home / stock / agn:cc / agn:cc news

AGN:CC News and Press, Algernon Pharmaceuticals Inc. From 01/09/23

Stock Information
Company Name: Algernon Pharmaceuticals Inc.
Stock Symbol: AGN:CC
Market: CNQC
Menu
AGN:CC AGN:CC Quote AGN:CC Short AGN:CC News AGN:CC Articles AGN:CC Message Board
Get AGN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
AGN:CC - The Power Play by The Market Herald Releases a New Interview with Algernon Pharmaceuticals Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / January 9, 2023 / The Power Play by The Market Herald has announced the release of a new interview with Algernon Pharmaceuticals discussing their latest news. The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know abou...
AGN:CC - Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil

VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it i...

AGN:CC - Algernon Pharmaceuticals forms Algernon NeuroScience subsidiary to advance DMT stroke program

(NewsDirect) Contact Details Proactive Canada Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com Copyright (c) 2023 TheNewswire - All rights reserved.

AGN:CC - Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company's Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

VANCOUVER, British Columbia, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it h...
AGN:CC - Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that the Un...

AGN:CC - Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that ...

AGN:CC - Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video

Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF)  – The company is focused on the disease area of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease. Algernon was recently...
AGN:CC - Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

VANCOUVER, British Columbia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has ente...

AGN:CC - Algernon Pharmaceuticals Announces Dr. Rick Strassman author of "DMT: The Spirit Molecule" to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

VANCOUVER, British Columbia, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that D...

AGN:CC - Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program

VANCOUVER, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it ha...
Previous 10 Next 10